MEP37208A - Pharmaceutical compositions comprising one or more steroids one or more tetrahydrofolate components and vitamin b12 - Google Patents

Pharmaceutical compositions comprising one or more steroids one or more tetrahydrofolate components and vitamin b12

Info

Publication number: MEP37208A
Authority: ME; Montenegro
Prior art keywords: tetrahydrofolic acid; tetrahydrofolic; vitamin; steroids; components
Prior art date: 2002-02-21

Application number

MEP-372/08A

Other languages

Bosnian (bs)

English (en)

Inventor

Bennink Herman Jan Tijmen Coelingh

Original Assignee

Bayer Schering Pharma Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-02-21

Filing date

2002-11-15

Publication date

2011-02-10

2002-11-15 Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag

2011-02-10 Publication of MEP37208A publication Critical patent/MEP37208A/xx

Links

150000003431 steroids Chemical class 0.000 title abstract 3
MSTNYGQPCMXVAQ-RYUDHWBXSA-N (6S)-5,6,7,8-tetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-RYUDHWBXSA-N 0.000 title abstract 2
239000008194 pharmaceutical composition Substances 0.000 title 1
239000005460 tetrahydrofolate Substances 0.000 title 1
RMRCNWBMXRMIRW-WYVZQNDMSA-L vitamin b12 Chemical compound N([C@@H]([C@@]1(C)[C@@](C)(CC(N)=O)[C@H](CCC(N)=O)\C(N1[Co+]C#N)=C(/C)\C1=N\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NCC(C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO RMRCNWBMXRMIRW-WYVZQNDMSA-L 0.000 title 1
MSTNYGQPCMXVAQ-KIYNQFGBSA-N 5,6,7,8-tetrahydrofolic acid Chemical class N1C=2C(=O)NC(N)=NC=2NCC1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-KIYNQFGBSA-N 0.000 abstract 2
241000124008 Mammalia Species 0.000 abstract 2
229930003779 Vitamin B12 Natural products 0.000 abstract 2
AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 abstract 2
239000003433 contraceptive agent Substances 0.000 abstract 2
238000002657 hormone replacement therapy Methods 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
239000011715 vitamin B12 Substances 0.000 abstract 2
235000019163 vitamin B12 Nutrition 0.000 abstract 2
QYNUQALWYRSVHF-OLZOCXBDSA-N (6R)-5,10-methylenetetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1C1)N)N1C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QYNUQALWYRSVHF-OLZOCXBDSA-N 0.000 abstract 1
VVIAGPKUTFNRDU-STQMWFEESA-N (6S)-5-formyltetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1C=O)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-STQMWFEESA-N 0.000 abstract 1
ZNOVTXRBGFNYRX-STQMWFEESA-N (6S)-5-methyltetrahydrofolic acid Chemical compound C([C@@H]1N(C=2C(=O)N=C(N)NC=2NC1)C)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-STQMWFEESA-N 0.000 abstract 1
AUFGTPPARQZWDO-YPMHNXCESA-N 10-formyltetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1)N)N(C=O)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 AUFGTPPARQZWDO-YPMHNXCESA-N 0.000 abstract 1
YCWUVLPMLLBDCU-STQMWFEESA-N 5-formimidoyltetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1C=N)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 YCWUVLPMLLBDCU-STQMWFEESA-N 0.000 abstract 1
229940011871 estrogen Drugs 0.000 abstract 1
239000000262 estrogen Substances 0.000 abstract 1
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 abstract 1
239000000583 progesterone congener Substances 0.000 abstract 1
229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Endocrinology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Reproductive Health (AREA)
Diabetes (AREA)
Gynecology & Obstetrics (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Steroid Compounds (AREA)

MEP-372/08A 2002-02-21 2002-11-15 Pharmaceutical compositions comprising one or more steroids one or more tetrahydrofolate components and vitamin b12 MEP37208A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP02075695		2002-02-21
PCT/NL2002/000741 WO2003070255A1 (en)	2002-02-21	2002-11-15	Pharmaceutical compositions comprising one or more steroids one or more tetrahydrofolate components and vitamin b12

Publications (1)

Publication Number	Publication Date
MEP37208A true MEP37208A (en)	2011-02-10

Family

ID=27741182

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MEP-372/08A MEP37208A (en)	2002-02-21	2002-11-15	Pharmaceutical compositions comprising one or more steroids one or more tetrahydrofolate components and vitamin b12

Country Status (28)

Country	Link
US (1)	US20050164977A1 (de)
EP (1)	EP1478373B1 (de)
JP (1)	JP5037779B2 (de)
KR (1)	KR100936827B1 (de)
CN (1)	CN1620302B (de)
AT (1)	ATE341333T1 (de)
AU (1)	AU2002343249B2 (de)
BR (1)	BR0215613A (de)
CA (1)	CA2476940C (de)
CR (1)	CR7420A (de)
CY (1)	CY1106273T1 (de)
DE (1)	DE60215224T2 (de)
DK (1)	DK1478373T3 (de)
EA (1)	EA007599B1 (de)
EC (1)	ECSP045305A (de)
ES (1)	ES2274107T3 (de)
HU (1)	HUP0402674A3 (de)
IL (2)	IL163579A0 (de)
ME (1)	MEP37208A (de)
MX (1)	MXPA04008185A (de)
NO (1)	NO20043932L (de)
NZ (1)	NZ534806A (de)
PL (1)	PL209558B1 (de)
PT (1)	PT1478373E (de)
RS (1)	RS50909B (de)
UA (1)	UA80965C2 (de)
WO (1)	WO2003070255A1 (de)
ZA (1)	ZA200407545B (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE102005023301B4 (de) *	2005-05-13	2012-05-31	Bayer Schering Pharma Aktiengesellschaft	Pharmazeutische Zusammensetzung enthaltend Gestagene und/oder Estrogene und 5-Methyl-(6S)-tetrahydrofolat
AU2012227235B2 (en) *	2005-05-13	2015-06-11	Bayer Intellectual Property Gmbh	Pharmaceutical composition comprising progestogens and/or estrogens and 5-methyl-(6S)-tetrahydrofolate
UY29527A1 (es) *	2005-05-13	2006-12-29	Schering Ag	Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
US20060293295A1 (en) *	2005-05-13	2006-12-28	Kai Strothmann	Pharmaceutical composition comprising progestogens and/or estrogens and 5-methyl- (6S)-tetrahydrofolate
MX2009000256A (es) *	2006-07-06	2009-02-18	Bayer Schering Pharma Ag	Preparaciones farmaceuticas para la anticoncepcion y para prevenir el riesgo de malformaciones congenitas.
US8617597B2 (en) *	2006-07-06	2013-12-31	Bayer Intellectual Property Gmbh	Pharmaceutical composition containing a tetrahydrofolic acid
CN101489563A (zh)	2006-07-06	2009-07-22	拜耳先灵医药股份有限公司	用于避孕和预防先天性畸形风险的药物制剂
AU2013202756B2 (en) *	2006-07-06	2015-06-04	Bayer Intellectual Property Gmbh	Pharmaceutical composition containing a tetrahydrofolic acid
EP1891959A1 (de) *	2006-08-14	2008-02-27	Bayer Schering Pharma Aktiengesellschaft	Pharmazeutische Zusammensetzung zur Kontrazeption und zur Verminderung des Risikos angeborener Fehlbildungen
GB0715502D0 (en) *	2007-08-08	2007-09-19	Univ Manchester	Methods
CA2714340A1 (en) *	2008-02-13	2009-08-20	Bayer Schering Pharma Aktiengesellschaft	Estradiol-containing drug delivery system
UY32836A (es)	2009-08-12	2011-03-31	Bayer Schering Pharma Ag	Partículas estabilizadas que comprenden 5-metil-(6s)-tetrahidrofolato
PL2324832T5 (pl) *	2009-11-09	2017-10-31	Biogena Naturprodukte Gmbh & Co Kg	Suplement diety przy przyjmowaniu hormonalnych środków antykoncepcyjnych
RS54880B1 (sr)	2011-06-01	2016-10-31	Estetra Sprl	Postupak proizvodnje intermedijarnih proizvoda estetrola
ME02585B (de)	2011-06-01	2017-06-20	Estetra Sprl	Verfahren zur herstellung von estetrolzwischenprodukten
EP2383279A1 (de)	2011-07-19	2011-11-02	Pantarhei Bioscience B.V.	Herstellungsverfahren für Esterol
US10357496B2 (en) *	2011-11-05	2019-07-23	South Alabama Medical Science Foundation	Methods, formulations, and kits for rapidly repleting folate levels in women
EP2782584B1 (de)	2011-11-23	2021-06-09	TherapeuticsMD, Inc.	Natürliche kombinierte hormonersatzformulierungen und -therapien
US9301920B2 (en)	2012-06-18	2016-04-05	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US10806697B2 (en)	2012-12-21	2020-10-20	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en)	2012-06-18	2020-10-20	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US20150196640A1 (en)	2012-06-18	2015-07-16	Therapeuticsmd, Inc.	Progesterone formulations having a desirable pk profile
US20130338122A1 (en)	2012-06-18	2013-12-19	Therapeuticsmd, Inc.	Transdermal hormone replacement therapies
US10537581B2 (en)	2012-12-21	2020-01-21	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en)	2012-12-21	2019-11-12	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en)	2012-12-21	2022-03-08	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en)	2012-12-21	2022-02-15	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en)	2012-12-21	2015-11-10	Therapeuticsmd, Inc.	Soluble estradiol capsule for vaginal insertion
US10568891B2 (en)	2012-12-21	2020-02-25	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
DK3079671T3 (en) *	2013-12-12	2017-12-11	Donesta Bioscience B V	Orally disintegrating solid dosage unit containing an estetrol component
AR100562A1 (es)	2014-05-22	2016-10-12	Therapeuticsmd Inc	Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
EP3701944B1 (de)	2015-06-18	2021-12-08	Estetra SRL	Schmelzende darreichungseinheit mit einer estetrolkomponente
CU24523B1 (es)	2015-06-18	2021-06-08	Estetra Sprl	Unidad de dosificación orodispersable que contiene un componente estetrol
MA44206B1 (fr)	2015-06-18	2021-04-30	Estetra Sprl	Comprimé orodispersible comprenant estetrol
LT3310345T (lt)	2015-06-18	2021-06-25	Estetra Sprl	Burnoje disperguojama tabletė, turinti estetrolio
US10328087B2 (en)	2015-07-23	2019-06-25	Therapeuticsmd, Inc.	Formulations for solubilizing hormones
WO2017173044A1 (en)	2016-04-01	2017-10-05	Therapeuticsmd Inc.	Steroid hormone compositions in medium chain oils
KR20180126582A (ko)	2016-04-01	2018-11-27	쎄러퓨틱스엠디, 인코퍼레이티드	스테로이드 호르몬 약제학적 조성물
CA3178291A1 (en)	2016-08-05	2018-04-12	Estetra Srl	Method for the management of dysmenorrhea and menstrual pain
TWI801561B (zh)	2018-04-19	2023-05-11	比利時商依思特拉私人有限責任公司	化合物及其用於緩解絕經相關症狀的用途
EP3781171B1 (de)	2018-04-19	2022-02-09	Estetra SRL	Verbindungen und deren verwendung zur linderung von menopause-assoziierten symptomen
US11633405B2 (en)	2020-02-07	2023-04-25	Therapeuticsmd, Inc.	Steroid hormone pharmaceutical formulations
TWI893101B (zh)	2020-04-16	2025-08-11	比利時商埃斯特拉有限責任公司	具有降低之副作用之避孕組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE262799T1 (de) *	1996-01-31	2004-04-15	Univ South Alabama	Lebensmittel und vitamin herstellungen mit natürlichem isomeren von reduzierten folaten
JP2002514170A (ja) *	1996-07-30	2002-05-14	エナージェティクス，インコーポレイティド	食品補充物
US6274564B1 (en) *	1996-09-18	2001-08-14	William J. Sarill	Compositions of cobalamin and related corrinoids, and uses thereof
US6220453B1 (en) *	1998-04-07	2001-04-24	Fuji Photo Film Co., Ltd.	Blood filter unit
CA2329005C (en) *	1998-04-17	2006-01-03	Ortho-Mcneil Pharmaceutical, Inc.	Folic acid-containing pharmaceutical compositions, and related methods and delivery systems
AU4573899A (en) *	1998-06-19	2000-01-05	Beth Israel Deaconess Medical Center	Dietary supplement for post-menopausal women
US6479545B1 (en) *	1999-09-30	2002-11-12	Drugtech Corporation	Formulation for menopausal women
DE10022510A1 (de) *	2000-05-10	2001-11-15	Basf Ag	Zusammensetzungen enthaltend Folsäure und reduziertes Folat
BG104880A (en) *	2000-10-24	2002-04-30	Иван ХРИСТОВ	Medicamentous preparation for multiple sclerosis treatment

2002
- 2002-11-15 JP JP2003569211A patent/JP5037779B2/ja not_active Expired - Fee Related
- 2002-11-15 EA EA200401014A patent/EA007599B1/ru not_active IP Right Cessation
- 2002-11-15 ME MEP-372/08A patent/MEP37208A/xx unknown
- 2002-11-15 UA UA20040907578A patent/UA80965C2/uk unknown
- 2002-11-15 EP EP02780174A patent/EP1478373B1/de not_active Expired - Lifetime
- 2002-11-15 WO PCT/NL2002/000741 patent/WO2003070255A1/en not_active Ceased
- 2002-11-15 US US10/505,555 patent/US20050164977A1/en not_active Abandoned
- 2002-11-15 AT AT02780174T patent/ATE341333T1/de active
- 2002-11-15 DE DE60215224T patent/DE60215224T2/de not_active Expired - Lifetime
- 2002-11-15 IL IL16357902A patent/IL163579A0/xx active IP Right Grant
- 2002-11-15 PL PL371441A patent/PL209558B1/pl not_active IP Right Cessation
- 2002-11-15 BR BR0215613-0A patent/BR0215613A/pt not_active IP Right Cessation
- 2002-11-15 RS YUP-733/04A patent/RS50909B/sr unknown
- 2002-11-15 HU HU0402674A patent/HUP0402674A3/hu unknown
- 2002-11-15 PT PT02780174T patent/PT1478373E/pt unknown
- 2002-11-15 NZ NZ534806A patent/NZ534806A/en not_active IP Right Cessation
- 2002-11-15 CA CA2476940A patent/CA2476940C/en not_active Expired - Fee Related
- 2002-11-15 ES ES02780174T patent/ES2274107T3/es not_active Expired - Lifetime
- 2002-11-15 DK DK02780174T patent/DK1478373T3/da active
- 2002-11-15 MX MXPA04008185A patent/MXPA04008185A/es active IP Right Grant
- 2002-11-15 KR KR1020047012983A patent/KR100936827B1/ko not_active Expired - Fee Related
- 2002-11-15 CN CN028282809A patent/CN1620302B/zh not_active Expired - Fee Related
- 2002-11-15 AU AU2002343249A patent/AU2002343249B2/en not_active Ceased
2004
- 2004-08-17 IL IL163579A patent/IL163579A/en not_active IP Right Cessation
- 2004-08-20 CR CR7420A patent/CR7420A/es not_active Application Discontinuation
- 2004-09-20 ZA ZA200407545A patent/ZA200407545B/en unknown
- 2004-09-20 NO NO20043932A patent/NO20043932L/no not_active Application Discontinuation
- 2004-09-21 EC EC2004005305A patent/ECSP045305A/es unknown
2006
- 2006-11-30 CY CY20061101724T patent/CY1106273T1/el unknown

Also Published As

Publication number	Publication date
CA2476940A1 (en)	2003-08-28
CY1106273T1 (el)	2011-10-12
PT1478373E (pt)	2007-01-31
IL163579A (en)	2011-03-31
JP5037779B2 (ja)	2012-10-03
RS73304A (sr)	2007-02-05
EP1478373A1 (de)	2004-11-24
EP1478373B1 (de)	2006-10-04
AU2002343249A1 (en)	2003-09-09
KR100936827B1 (ko)	2010-01-14
EA007599B1 (ru)	2006-12-29
IL163579A0 (en)	2005-12-18
EA200401014A1 (ru)	2006-10-27
DE60215224D1 (de)	2006-11-16
ECSP045305A (es)	2004-10-26
PL209558B1 (pl)	2011-09-30
HUP0402674A2 (hu)	2005-04-28
JP2005523283A (ja)	2005-08-04
MXPA04008185A (es)	2004-11-26
DE60215224T2 (de)	2007-08-23
BR0215613A (pt)	2004-12-07
US20050164977A1 (en)	2005-07-28
NO20043932L (no)	2004-11-19
DK1478373T3 (da)	2007-01-15
NZ534806A (en)	2006-05-26
ES2274107T3 (es)	2007-05-16
HUP0402674A3 (en)	2012-12-28
CN1620302A (zh)	2005-05-25
PL371441A1 (en)	2005-06-13
KR20040094711A (ko)	2004-11-10
UA80965C2 (en)	2007-11-26
CR7420A (es)	2006-02-06
HK1078780A1 (en)	2006-03-24
ZA200407545B (en)	2006-06-28
RS50909B (sr)	2010-08-31
WO2003070255A1 (en)	2003-08-28
CN1620302B (zh)	2011-04-27
AU2002343249B2 (en)	2009-02-05
CA2476940C (en)	2011-11-01
ATE341333T1 (de)	2006-10-15

Publication	Publication Date	Title
EA200401014A1 (ru)	2006-10-27	Фармацевтические композиции, содержащие один или несколько стероидов, один или несколько тетрагидрофолатных компонентов и витамин в
AU739544B2 (en)	2001-10-18	The use of tetrahydrofolates in natural stereoisomeric form for the production of a pharmaceutical preparation suitable for the influencing the homocysteine level, particularly for assisting the remethylation of homocysteine
RU98111617A (ru)	2000-02-27	Применение тетрагидрофолатов естественной стереоизомерной формы при получении фармацевтической композиции, предназначенной для воздействия на уровень гомоцистеина, в частности для поддержания процесса реметилирования гомоцистеина
MEP38008A (en)	2011-02-10	Drospirenone for hormone replacement therapy
WO2006099233B1 (en)	2007-06-28	Compositions and methods for the treatment of osteoporosis and inflammatory joint disease
EP2037935A1 (de)	2009-03-25	Pharmazeutische zubereitung zur kontrazeption und zur verminderung des risikos angeborener fehlbildungen
JP2008520574A5 (de)	2012-04-19
PT100409A (pt)	1993-08-31	Utilizacao de inibidores de aromatase, por exemplo derivados de imidazopiridina, para a anticoncepcao em primatas femeas sem afectar o ciclo menstrual
JP2009514776A5 (de)	2011-03-24
US20060216361A1 (en)	2006-09-28	Compositions and methods for the treatment of osteoporosis and inflammatory joint disease
Paz-Ares et al.	2002	Pemetrexed in bladder, head and neck, and cervical cancers
JP2004538262A5 (de)	2005-12-22
IL317418A (en)	2025-02-01	Stable pharmaceutical preparations comprising 5,10-methylene-(6R)-tetrahydrofolic acid and NaCl
WO2008057738A1 (en)	2008-05-15	Isoflavone-containing compositions for the treatment of osteoporosis and inflammatory joint disease
HU9900213D0 (en)	1999-03-29	Pharmaceutical compositions for diminishing side-effects of hormone-containing compositions
EP1891959A1 (de)	2008-02-27	Pharmazeutische Zusammensetzung zur Kontrazeption und zur Verminderung des Risikos angeborener Fehlbildungen
JP2005298493A (ja)	2005-10-27	肌あれ予防および／または治療用医薬組成物
MXPA98004683A (en)	1999-09-20	The use of tetrahydrofolates in a natural stereoisomeric form for the production of an adequate pharmaceutical preparation to influence the homocysteine level, particularly to help in the homociste remedy